Senior Manager​/Associate Director, Access Marketing

Who We Are

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X‑TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.

Our Phase 3 epilepsy program also includes a second FOS study, X‑TOLE3, which would support regulatory submissions outside the U.S., and the X‑ACKT study in primary generalized tonic‑clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X‑NOVA clinical trial.

In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early‑stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN
1701 (targeting Nav
1.7) and XEN
1120 (targeting Kv7). Nav
1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof‑of‑concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

We are seeking a Senior Manager/Associate Director, Access Marketing, to join our team. This person will be an integral member of the US Market Access team, responsible for executing the azetukalner access strategy to ensure payer and patient access. This role will play a significant role in the development and execution of the payer value proposition through various market access channels and the patient services marketing materials needed to support patient access.

This individual will play a pivotal role in orchestrating communication and alignment across the market access, marketing, and sales to ensure optimal azetukalner coverage and pull‑through efforts. Externally, this individual must successfully partner with various agencies to effectively lead the implementation of access marketing strategies and tactical plans.

This position reports to the Director of Value & Access and will be based out of Boston, MA, USA in our Needham office. We will consider other jurisdictions for exceptional candidates. The level of the position will be commensurate with the candidate’s education and industry experience. This role is a hybrid position, requiring a minimum of 2 days per week in the office.

• Support the execution of pre‑launch and post‑launch market access strategy and tactical plan
• Lead the development and evolution of a strong product value proposition for payers, population‑based decision‑makers, and channel customers
• Lead the development of patient‑ and office‑facing materials and enhance resources to support patient access
• Develop and gain approvals for access marketing tactics and materials that effectively communicate the value story. This may include items “above‑brand” and/or branded promotional pieces through internal review process (ex. PRC), training of internal stakeholders (ex. field account teams), and development of KPIs to measure effectiveness
• Collaborate with medical affairs and HEOR/RWE to inform real‑world evidence generation plans and…